DOI: https://doi.org/10.30841/2307-5090.3(62).2017.117657

Решение проблемы преждевременной эякуляции в практике уролога

І. І. Горпинченко, В. В. Спиридоненко

Аннотация


В обзоре, посвященном актуальным проблемам преждевременной эякуляции, изложены современные позиции классификации, этиопатогенеза и лечения данного состояния. Современный представитель селективных ингибиторов обратного захвата серотонина – дапоксетин, является единственным эффективным препаратом, применяемым для коррекции преждевременной эякуляции различного генеза. В статье приведены современные данные относительно его механизмов действия в свете новых научных исследований.


Ключевые слова


преждевременная эякуляция; дапоксетин

Полный текст:

PDF

Литература


Горпинченко И.И., Спиридоненко В.В. Преждевременная эякуляция и возможность ее эффективной коррекции (2017) // Здоровье мужчины. – No 2 (61). – С. 75–78.

Althof S.F. et al. (2014) An update on the International Society of Sexual Medecine’s guidelines for the diagnosis and treatment of premature ejaculation // Sex. Med, 11: P. 1392.

Laumann E., Nicolosi A., Glasser D., Paik A., Gingell C., Moreira E., et al. (2005) Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 17: 39–57.

Nicolosi A., Laumann E., Glaser D., Moreira E., Paik A., Gingell C. (2004) Global study of sexual attitudes and behaviors investigator’s group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 64: 991–997.

Montorsi F. (2005) Prevalence of premature ejaculation: a global and regional perspective. J Sex Med 2(Suppl. 2): 96–102.

Jannini E., Lenzi A. (2005) Epidemiology of premature ejaculation. Curr Opin Urol 15: 399–403.

Porst H., Montorsi F., Rosen R., Gaynor L., Grupe S., Alexander J. (2007) The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 51: 816–823.

Giuliano F., Bernabe J., Gengo P., Alexandre L., Clement P. (2007) Effect of acute dapoxetine administration on the pudendal motoneuron reflex in anesthetized rats: comparison with paroxetine. J Urol 177: 386–389.

Patrick D., Althof S., Pryor J., Rosen R., Rowland D., Ho K., et al. (2005) Premature ejaculation: an observational study of men and their partners. J Sex Med 2: 358–367.

Laumann E., Paik A., Rosen R. (1999) Sexual dysfunction in the United States: prevalence and predictors. JAMA 281: 537–544.

Waldinger M., Quinn P., Dilleen M., Mundayat R., Schweitzer D., Boolell M. (2005a) A multinational population survey of intravaginal ejaculation latency time. J Sex Med 2: 492–497.

Hatzimouratidis K., Giuliano F., Moncada I. et al. (2002). EAU GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature ejaculation// Eur. Urol. – Sep. 62(3): P. 543–52.

McMahon C. (2008) Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies – part II – study design, outcome measures, data analysis, and reporting. J Sex Med 5: 1817–1833.

McMahon C. (2002) Long term results of treatment of premature ejaculation with selective serotonin reuptake inhibitors. Int J Impot Res 14 (Suppl. 3): S19.

Waldinger M., Hengeveld M., Zwinderman A., Olivier B. (1998a) An empirical operationalization of DSM-IV diagnostic criteria for premature ejaculation. Int J Psychiatry Clin Pract 2: 287–293.

Segraves R. (2010) Considerations for an evidence-based definition of premature ejaculation in the DSM-V. J Sex Med 7: 672–679.

Porst H., McMahon C., Althof S., Sharlip I., Bull S., Aquilina J., et al. (2010) Baseline characteristics and treatment outcome for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of three phase 3 dapoxetine trials. J Sex Med 7: 2231–2242.

Schapiro B. (1943) Premature ejaculation, a review of 1130 cases. J Urol 50: 374–379.

Godpodinoff M. (1989) Premature ejaculation: clinical subgroups and etiology. J Sex Marital Ther 15: 130–134.

Waldinger M. (2006) The need for a revival of psychoanalytic investigations into premature ejaculation. J Mens Health & Gender 3: 390–396.

Waldinger M., Schweitzer D. (2006) Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II – proposals for DSM-V and ICD-11 J Sex Med 3: 693–705.

Serefoglu E., Yaman O., Cayan S., Asci R., Orhan I., Usta M., et al. (2011) The comparison of premature ejaculation assessment questionnaires and their sensitivity for the four premature ejaculation syndromes: results from the Turkish society of andrology sexual health survey. J Sex Med 8: 1177–1185.

Hyun J., Kam S., Kwon O. (2008) Changes of cerebral current source by audiovisual erotic stimuli in premature ejaculation patients. J Sex Med 5: 1474–1481.

McMahon C., Abdo C., Incrocci L., Perelman M., Rowland D., Waldinger M., et al. (2004) Disorders of orgasm and ejaculation in men. J Sex Med 1: 58–65.

Pattij T., Olivier B., Waldinger M. (2005) Animal models of ejaculatory behavior. Curr Pharm Des 11: 4069–4077.

Waldinger M., Rietschel M., Nothen M., Hengeveld M., Olivier B. (1998c) Familial occurrence of primary premature ejaculation. Psychiatr Genet 8: 37–40.

Jern P., Santtila P., Witting K., Alanko K., Harlaar N., Johansson A., et al. (2007) Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. J Sex Med 4: 1739–1749.

Qin X, Ma X, Tu D, Luo Z, Huang J, Mo C. (2017). The effect of 8-OH-DPAT and dapoxetine on gene expression in the brain of male rats during ejaculation. Acta Pharm Sin B. May;7(3):381-389.

Janssen P., Bakker S., Rethelyi J., Zwinderman A., Touw D., Olivier B., et al. (2009) Serotonin transporter promoter region (5-HTTLPR) olymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J Sex Med 6: 276–284.

Hartmann U., Schedlowski M., Kruger T. (2005) Cognitive and partner-related factors in rapid ejaculation: differences between dysfunctional and functional men. World J Urol 10: 10.

Screponi E., Carosa E., Di Stasi S., Pepe M., Carruba G., Jannini E. (2001) Prevalence of chronic prostatitis in men with premature ejaculation. Urology 58: 198–202.

Carani C., Isidori A., Granata A., Carosa E., Maggi M., Lenzi A., et al. (2005) Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 90: 6472–6479.

Adson D., Kotlyar M. (2003) Premature ejaculation associated with citalopram withdrawal. Ann Pharmacother 37: 1804–1806.

Peugh J., Belenko S. (2001) Alcohol, drugs and sexual function: a review. J Psychoactive Drugs 33: 223–232.

Waldinger M., Schweitzer D. (2008) The use of old and recent DSM definitions of premature ejaculation in observational studies: a contribution to the present debate for a new classification of PE in the DSM-V. J Sex Med 5: 1079–1087.

Castiglione F, Albersen M, Hedlund P, Gratzke C, Salonia A, Giuliano F.Current. (2016) Pharmacological Management of Premature Ejaculation: A Systematic Review and Meta-analysis. Eur Urol. May; 69(5):904–16.

Cooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A. (2015). Interventions to treat premature ejaculation: a systematic review short report. Health Technol Assess. Mar;19(21):1-180.

Porst et al. (2007) The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eurol. Urol.; 51: 816–824.

Waldiner (2003) Towards evidenced based drug treatment research on premature ejaculation: a critical evaluation of methodology // J Impotence Res 2003; 15(5): 309–313.

Salonia A., Rocchini L., Sacca A., Pellucchi F., Ferrari M., Carro U., et al. (2009) Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Sex Med 6: 2868–2877.

Livni E., Satterlee W., Robey R., Alt C., Van Meter E., Babich J., et al. (1994) Synthesis of [11C] dapoxetine · HCl, a serotonin re-uptake inhibitor: biodistribution in rat and preliminary PET imaging in the monkey. Nucl Med Biol 21: 669–675.

Dresser M., Kang D., Staehr P., Gidwani S., Guo C., Mulhall J., et al. (2006) Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal. J Clin Pharmacol 46: 1023–1029.

Dresser M., Lindert K., Lin D. (2004) Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clin Pharmacol Ther 75: 113 (abstract P111).

Modi N., Dresser M., Simon M., Lin D., Desai D., Gupta S. (2006) Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 46: 301–309.

Hellstrom W., Althof S., Gittelman M., Streidle C., Ho K., Kell S., et al. (2005) Dapoxetine for the treatment of men with premature ejaculation (PE): dose-finding analysis. J Urol 173: 238 (abstract 877).

Hellstrom W., Gittelman M., Althof S. (2004) Dapoxetine HCl for the treatment of premature ejaculation: a phase II, randomised, double-blind, placebo controlled study. J Sex Med 1(Suppl. 1): 59 (abstract 097).

Pryor J., Althof S., Steidle C., Rosen R., Hellstrom W., Shabsigh R., et al. (2006) Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 368: 929–937.

Buvat J., Tesfaye F., Rothman M., Rivas D., Giuliano F. (2009) Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 55: 957–967.

Kaufman J., Rosen R., Mudumbi R., Tesfaye F., Hashmonay R., Rivas D. (2009) Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 103: 651–658.

McMahon C., Kim S., Park N., Chang C., Rivas D., Tesfaye F., et al. (2010) Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 7: 256–268.

Waldinger M., Zwinderman A., Olivier B., Schweitzer D. (2007) The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med 4: 1028–1037.

Montague, D. K.; Jarow, J.; Broderick, G. A.; Dmochowski, R. R.; Heaton, J. P.; Lue, T. F.; Sharlip, I. D. (2004). «AUA guideline on the pharmacologic management of premature ejaculation. [Guideline Practice Guideline]». J Urol. 172 (1): 290–294.

Modi N., Kell S., Aquilina J., Rivas D. (2008) Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin. J Clin Pharmacol 48: 1438–1450.

Abu El-Hamd M, Abdelhamed A. Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in

treatment of patients with premature ejaculation: A randomized placebo-controlled clinical trial (2017). Andrologia. May 12. doi: 10.1111/and.12829.

Lee WK, Lee SH, Cho ST, Lee YS, Oh CY, Yoo C, Cho JS, Lee SK, Yang DY. (2013). Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J Sex Med. Nov;10(11):2832–41.

Russo A, Capogrosso P, Ventimiglia E, La Croce G, Boeri L, Montorsi F, Salonia A. (2016) Efficacy and safety of dapoxetine in treatment of premature ejaculation: anиevidence-based review. Int J Clin Pract. Sep;70(9):723-33.

Waldinger M.D., Schweitzer D.H. (2008) Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case. J Sex Med. Apr;5(4):966–97.

McMahon C.G. (2012) Dapoxetine: a new option in the medical management of premature ejaculation // Ther Adv Urol. Oct; 4(5): 233–251.

Atmaca M., Kuloglu M., Tezcan E., Semercioz A. (2002) The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res 14: 502–505.

Black K., Shea C., Dursun S., Kutcher S. (2000) Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 25: 255–261.

Hutchinson K., Cruickshank K., Wylie K. A. (2012) benefit-risk assessment of dapoxetine in the treatment of premature ejaculation. Drug Saf. May 1;35(5):359–72.




Copyright (c) 2017 Здоровье мужчины

Creative Commons License
Эта работа лицензирована Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-5547 (Online), ISSN 2307-5090 (Print)